



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Confirmation No.: 2502

SAMAL, et al.

Art Unit: 1648

Application No.: 09/926,431

Examiner: Foley, Shanon A.

Filed: October 31, 2001

Attorney Dkt. No.: 108172-00070

For: PRODUCTION OF NOVEL NEWCASTLE DISEASE VIRUS STRAINS
FROM cDNAs AND IMPROVED LIVE ATTENUATED NEWCASTLE DISEASE
VACCINES

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date: October 15, 2003

Sir:

In response to the Office Action dated September 15, 2003, Applicants hereby elect with traverse to prosecute the subject matter in claims 1-7, 19 and 26-27 of Group I, drawn to a Newcastle disease vaccine comprising a Newcastle Disease Virus Z.

This election is made with traverse because there would be no undue burden to examine claims 1-25 on the merits. In particular, applicants request rejoinder of Group I and VI because the Newcastle Disease Virus Z of Group I can be prepared with the method of claims 13-18 of Group VI.

Applicants reserve the right to file one or more divisional applications directed to the non-elected claims.


In the event that this paper is deemed not timely, applicants petition for an appropriate extension of time. The Commissioner is hereby authorized to charge

RECEIVED
OCT 20 2003
TECH CENTER 1600/2900

any fee deficiency or credit any overpayment associated with this communication to Deposit Account No. 01-2300 referencing the docket number of 108172-00070.

Respectfully submitted,

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC



King L. Wong
Reg. No. 37,500

Customer No. 004372

1050 Connecticut Avenue, N.W., Suite 400
Washington, D.C. 20036-5339

Tel: (202) 857-6435

Fax: (202) 638-4810

KLW:elp
204996_1.DOC